Jensen R T
Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892-1804, USA.
Yale J Biol Med. 1994 May-Aug;67(3-4):195-214.
It is fitting that the Zollinger-Ellison syndrome (ZES) be included in the Lester Dragstedt Symposium because Dr. Dragstedt had a long-time interest in this disease, having been one of the five discussants of the original article and subsequently reporting with Dr. Oberhelman on nine cases. The approach to therapy of ZES has been controversial from the beginning, and a number of controversies remain. In this article, four different controversies are analyzed from the prospective of the past (Zollinger-Dragstedt era, 1955-1980), present and what may happen in the future in light of recent results. Specifically analyzed are: 1) the role of gastric surgery in the management; 2) whether gastrinoma removal without aggressive resection in patients with ZES without MEN-I is the preferred surgical therapy; 3) whether patients with MEN-I should undergo routine surgical exploration; and 4) whether most gastrinomas will be localized preoperatively. An analysis of recent advances suggests there may be marked changes in the future from our current and our past approaches.
将佐林格-埃利森综合征(ZES)纳入莱斯特·德拉格斯泰特研讨会是恰当的,因为德拉格斯泰特博士长期以来一直关注这种疾病,他是最初那篇文章的五名讨论者之一,后来还与奥伯赫尔曼博士共同报告了9例病例。ZES的治疗方法从一开始就存在争议,并且现在仍有一些争议。在本文中,从过去(佐林格-德拉格斯泰特时代,1955 - 1980年)、现在以及根据近期结果展望未来可能发生的情况这几个方面,对四个不同的争议点进行了分析。具体分析的内容包括:1)胃部手术在治疗中的作用;2)对于无MEN - I的ZES患者,不进行积极切除而仅切除胃泌素瘤是否是首选的手术治疗方法;3)患有MEN - I的患者是否应接受常规手术探查;4)大多数胃泌素瘤术前是否能够定位。对近期进展的分析表明,未来我们当前和过去的治疗方法可能会有显著变化。